Biotechnology

Staidson BioPharm

Staidson BioPharm released FY2025 earnings on April 27 After-Market (BJT), actual revenue CNY 220.23 M (forecast CNY 336.12 M), actual EPS CNY -0.16 (forecast CNY -0.03)

Staidson BioPharm released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 39.69 M, actual EPS CNY -0.1149

Staidson BioPharm released FY2026 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 46.9 M, actual EPS CNY -0.02

Staidson BioPharm FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

Staidson BioPharm to release FY2025 earnings on March 24 After-Market (BJT), forecast revenue CNY 336.12 M, EPS CNY -0.03

Staidson BioPharm released FY2025 Q3 earnings on October 28 After-Market BJT, actual revenue CNY 54.94 M, actual EPS CNY -0.011

Staidson BioPharm released FY2025 9 Months earnings on October 28 After-Market BJT, actual revenue CNY 180.54 M, actual EPS CNY -0.0625

Staidson BioPharm FY2025 Q3 Earnings Release on October 29 After-Market BJT

Staidson BioPharm released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), Actual Revenue: CNY 125.6 M, Actual EPS: CNY -0.05

Staidson BioPharm released FY2025 Q2 earnings on August 25 After-Market BJT, actual revenue CNY 62.38 M, actual EPS CNY -0.0466

Staidson BioPharm FY2025 Semi-Annual Earnings Release on August 26, 2025 (BJT)

Shutai Shen's BDB-001 Injection Phase II Clinical Trial Completed

Shutaishen Secretary Explains Future Prospects

Shutaishen's STSA-1002 Injection Shows Preliminary Efficacy and Safety in Ib/II Phase Clinical Trials

TF Securities Gives ShuTaishen a Buy Rating

Shutai Shen's STSP-0601 Receives Breakthrough Therapy Designation

Shutai Shen's Stock Price Soars Over 400% in Two Months

Shutaishen's Subsidiary Product STSP-0601 Included in Priority Review Program

Shutaishen's Subsidiary Drug Application Accepted by NMPA

Innovative drug concept stocks continue to rise, Shute Shen hits the upper limit

688308

605499

000592

603538

000070

300204

On March 31, institutions net bought 17 stocks including Pingtan Development, with net buying amounts of CNY 234 million for Pingtan Development, CNY 219 million for OKE, and CNY 150 million for SDGI. At the same time, institutions net sold EASTROC BEVERAGE for CNY 363 million, Staidson BioPharm for CNY 287 million, and Menovo for CNY 134 million

36Kr

EASTROC BEVERAGE

PINGTAN DEVELOPMENT

Menovo

SDGI

Institutions bought Pingtan Development and 17 other stocks today, selling Eastroc Beverage for 363 million yuan

Pharmaceutical company Staidson BioPharm (Shenzhen: 300204) saw its stock price plummet by 8.5%, currently reported at 34.02 yuan. The company announced that its third-largest shareholder, Xiangtang Group, plans to reduce its holdings by no more than 4.7777 million shares, accounting for 1% of the total share capital. Based on yesterday's closing price, the cash amount that Xiangtang Group will realize is approximately 178 million yuan. Xiangtang Group currently holds 27.1396 million shares, accounting for 5.68% of the total share capital. This year, Staidson's stock price has increased by 361%

etnet

"A-Share Focus" Staidson BioPharm plummets 8.5%, the third-largest shareholder plans to reduce holdings

Staidson BioPharm today hit a 20% limit up, with a transaction amount of 2.427 billion yuan and a turnover rate of 15.01%. According to the after-hours dragon and tiger list data, 5 institutional special seats net bought 229 million yuan, while 1 institutional special seat net sold 30.9812 million yuan

Zhitong

Staidson BioPharm today hit a 20% limit up, with 5 institutional special seats net buying 229 million yuan

According to the Zhitong Finance APP, Staidson BioPharm released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 181 million yuan, a year-on-year decrease of 30.82%. The net loss attributable to shareholders of the listed company was 30.6895 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 34.3569 million yuan. The basic loss per share was 0.06 yuan

Staidson BioPharm released its performance for the first three quarters, with a net loss attributable to the parent company of 30.6895 million yuan

Staidson BioPharm announced that on October 24, 2025, the company received a notice from the Shenzhen Stock Exchange stating that its application documents for issuing shares to specific targets have been accepted. This issuance still needs to be approved by the Shenzhen Stock Exchange and obtain the registration decision from the China Securities Regulatory Commission before it can be implemented. There is uncertainty regarding whether it will pass the review and the timeline, and the company will disclose progress in a timely manner

Staidson BioPharm: Application for stock issuance to specific objects accepted by Shenzhen Stock Exchange

300683

002004

688098

603367

300878

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit

HITECK

HUAPONT LIFE SCIENCES

Shen Lian Biomedical

CISEN

WECOME

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

600276

688513

300111

002755

The pharmaceutical sector fell at the beginning of trading, with SUNFLOWER dropping 10%, ASK PHARM falling over 7%, and multiple stocks including Staidson BioPharm, Hengrui Pharma, and EASTON BIOPHARMACEUTICALS declining

Hengrui Pharma

EASTON BIOPHARMACEUTICALS

SUNFLOWER

ASK PHARM

The pharmaceutical sector fell at the beginning of trading, with SUNFLOWER dropping 10%

According to the Shanghai Sunshine Pharmaceutical Procurement Network news on September 15, the Shanghai Municipal Pharmaceutical Centralized Bidding Procurement Affairs Management Office issued a notice stating that, in accordance with relevant documents from the National Healthcare Security Administration, due to some companies failing to adjust drug prices as required, the procurement qualifications for certain drugs will be suspended starting from 0:00 on September 16, 2025. A total of 10 drugs, including 15 specifications, will have their procurement qualifications suspended, involving 11 companies such as Staidson BioPharm and Sichuan Baile Pharmaceutical Co., Ltd

10 drugs have been suspended from procurement qualifications, involving Staidson BioPharm, Baillie Pharmaceutical, and other companies

Staidson BioPharm(300204.SZ)